You feel flat by 3 p.m., your workouts stalled, and an urgent-care panel came back "low normal" with a shrug. Before you start any hormone path, there's one measurement worth banking first — because some therapies can quietly close a door you want to keep open.
The tradeoff nobody explained at urgent care
Here's the mechanism that matters. Your brain runs a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases GnRH, which tells the pituitary to release LH and FSH, which tell the testes to make testosterone *and* to keep sperm production running [1]. When you add testosterone from the outside — injections, gels, pellets — your brain reads the high blood level and dials down its own signal. LH and FSH drop, and the intratesticular testosterone and FSH signaling that sperm production depends on drop with them. That's why exogenous testosterone can suppress spermatogenesis; the effect is well enough established that testosterone has been studied as a male contraceptive [2].
For a founder who plans to start a family in the next few years, that's not a footnote. It's the whole decision.
This is educational information, not medical advice, and it isn't a recommendation to take any specific drug. Whether any therapy fits you is a decision for an independent licensed provider.
Why a semen analysis is the baseline to bank
A blood testosterone number tells you almost nothing about fertility. Sperm production is a separate output of the same axis, and the only way to see it directly is a semen analysis. Banking that number *before* you change anything gives a provider two things: a true starting point, and a way to interpret any future change. Without a pre-therapy baseline, you can't tell whether a low count six months from now was caused by therapy, was always there, or reflects something unrelated.
The World Health Organization publishes reference ranges from studies of men who conceived within about a year. These are the fifth-percentile lower reference limits — the low end of the fertile range, not a pass/fail line [3]:
- Semen volume: about 1.4 mL
- Sperm concentration: about 16 million per mL
- Total sperm number: about 39 million per ejaculate
- Total motility: about 42%
- Normal morphology: about 4%
A single result below a reference limit doesn't diagnose infertility, and a result above it doesn't guarantee anything — which is exactly why a provider looks at the whole picture, often repeating the test, since sperm parameters vary week to week [3].
Source: [3] WHO laboratory manual for the examination and processing of human semen, 6th edition
What the numbers tell a provider — alongside your hormones
Parsed together, semen parameters and a hormone panel start to tell a story. If total testosterone is genuinely low and LH and FSH are low or "inappropriately normal," that pattern points toward a central (secondary) problem in the pituitary signal rather than a primary testicular one [1]. That distinction shapes everything downstream, because the fertility-preserving strategies work by *raising* the brain's own signal rather than replacing testosterone from outside.
The Endocrine Society's clinical practice guideline is direct on the fertility point: it recommends against prescribing standard testosterone therapy to men who are planning fertility in the near term, precisely because of the suppression effect [4]. That guidance is the reason a fertility-minded conversation looks different from a standard "low T" visit.
mL · marker = WHO lower limit
Source: [3] WHO laboratory manual for the examination and processing of human semen, 6th edition
Where enclomiphene enters the conversation
Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator. Mechanistically, it blocks estrogen receptors at the hypothalamus and pituitary, which reduces the brain's negative-feedback signal — so the pituitary releases *more* LH and FSH, and the testes are driven to make more of their own testosterone while spermatogenesis signaling stays on [5]. In other words, it works with the axis instead of overriding it. Clomiphene-class agents have been studied in men with secondary hypogonadism for exactly this reason [5].
Important framing, no hype: this is not a promise. Whether enclomiphene, clomiphene, an aromatase-based approach, hCG, or standard testosterone is appropriate — or whether hormone therapy is appropriate at all — is a clinical judgment an independent provider makes from your labs, your history, and your goals. A prescription is never guaranteed.
One practical note: some formulations in this category are available only as compounded preparations. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
A sensible pre-therapy baseline to have on hand
Think of this as the file a good provider wishes you'd already built:
- Semen analysis — ideally more than one, given natural variability [3]
- Total (and often free) testosterone, drawn in the morning when levels peak, and confirmed on a repeat because a single reading fluctuates [4]
- LH and FSH — to separate a central signaling issue from a testicular one [1]
- Estradiol, prolactin, and other pituitary context as a provider directs
- Symptom and goal history — the afternoon crash, the flat training, and, critically, your family-planning timeline
Banking this once means every later decision is measured against a real starting line rather than a guess.
Source: [1] Male Hypogonadism (StatPearls / NCBI Bookshelf), [3] WHO laboratory manual for the examination and processing of human semen, 6th edition, [4] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
For a different reader, a related principle
If you're reading this after a surgical or early menopause — the night sweats, joint aches, and fog that arrived a decade "early" — the specifics differ, but the principle holds: a thorough baseline and a provider who builds an *ongoing* plan beat a one-time handoff. Surgical menopause is its own clinical situation, and the value is continuity — someone who tracks your labs and symptoms over time rather than a single consult that ends the moment it starts. The therapies and testing are different; the standard of "measure first, follow through" is the same.
Skepticism, answered honestly
*"Does any hormone path secretly tank fertility?"* Standard testosterone therapy can suppress it — that's not a secret, it's a documented mechanism [2][4]. Fertility-sparing strategies exist specifically because of it, which is exactly why the pre-therapy semen analysis matters.
*"Is an online visit more legit than my in-person PCP?"* It's not about the channel. It's about whether the provider treats fertility as a first-class goal, orders the right baseline, and follows the relevant guideline [4]. A dismissive "you're fine" isn't a standard of care; it's the absence of one.
*"Does 'low normal' even qualify me?"* Qualification isn't a single number. A provider weighs symptoms, repeated labs, LH/FSH pattern, and your goals together [1][4] — which is the whole reason a real baseline beats a shrug.
Where Velri fits
Velri is a technology and coordination company — not a medical provider. What Velri can do is help organize the parts: coordinate lab work (including a semen analysis and hormone panel) so you arrive with a real baseline, connect you with an independent, licensed provider group for an evaluation, and — *only if that provider decides a prescription is appropriate* — coordinate fulfillment through an independent, licensed pharmacy. Care is delivered by the independent providers; medications are dispensed by the pharmacies. Velri coordinates the logistics so your baseline, your visit, and any follow-through stay connected over time. Nothing here is a promise of treatment, and none of it is medical advice.
